Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13

Authors: Jinqi Xue, Zhiguang Chen, Xi Gu, Yang Zhang, Wenhai Zhang

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Breast cancer is a threat to the health of women, and metastasis of breast cancer cells plays an important role in the deterioration of breast cancer. MicroRNAs play a critical role in the tumorigenesis and development of breast cancer. MicroRNA-148a (miR-148a) is associated with the growth and metastasis of tumor cells. In the present study, we investigated the role of miR-148a in migration of breast cancer cells as well as the underlying mechanism. MiR-148a was found to inhibit the proliferation and migration of breast cancer cells. To further explore the mechanism through which miR-148a plays its antitumor role, matrix metalloproteinase-13 (MMP-13) was identified as a target of miR-148a by western blot and luciferase reporter assay. Moreover, silence of MMP-13 mimicked the effect of miR-148a, whereas overexpression of MMP-13 rescued the impaired migration caused by miR-148a. Our study demonstrates that miR-148a inhibits the migration of breast cancer cells by targeting MMP-13 and also lays theoretical foundation for further exploration for the function of miR-148a.
Literature
1.
Zielinska HA, Bahl A, Holly JM, Perks CM. Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor i and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press). 2015;7:9–19.
2.
Foshay KM, Gallicano GI. Small RNAs, big potential: the role of microRNAs in stem cell function. Curr Stem Cell Res Ther. 2007;2:264–71.CrossRefPubMed
3.
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–8.CrossRefPubMed
4.
5.
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.CrossRefPubMed
6.
7.
Pan L, Huang S, He R, Rong M, Dang Y, Chen G. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 2014;19:68.CrossRefPubMedPubMedCentral
8.
Xia J, Guo X, Yan J, Deng K. The role of miR-148a in gastric cancer. J Cancer Res Clin Oncol. 2014;140:1451–6.CrossRefPubMed
9.
Zhang SL, Liu L. MicroRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. Exp Ther Med. 2015;9:579–84.PubMed
10.
Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.CrossRefPubMed
11.
Aydogdu E, Katchy A, Tsouko E, Lin CY, Haldosen LA, Helguero L, et al. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis. 2012;33:1502–11.CrossRefPubMed
12.
Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25b. Lab Invest. 2011;91:1472–9.CrossRefPubMed
13.
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011;18:1702–10.CrossRefPubMedPubMedCentral
14.
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 2013;5:3–13.CrossRefPubMed
15.
Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin Cancer Biol. 1996;7:147–54.CrossRefPubMed
16.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.CrossRefPubMed
17.
Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS. 1999;107:45–53.CrossRefPubMed
18.
Corte MD, Gonzalez LO, Corte MG, Quintela I, Pidal I, Bongera M, et al. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma. Int J Biol Markers. 2005;20:242–8.PubMed
19.
Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol. 2002;55:758–62.CrossRefPubMedPubMedCentral
20.
Yang B, Gao J, Rao Z, Shen Q. Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer. Scand J Clin Lab Invest. 2012;72:501–5.CrossRefPubMed
21.
Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer. 2008;8:83.CrossRefPubMedPubMedCentral
22.
Yeh WL, Lu DY, Lee MJ, Fu WM. Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia. 2009;57:454–64.CrossRefPubMed
23.
Inoue A, Takahashi H, Harada H, Kohno S, Ohue S, Kobayashi K, et al. Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol. 2010;37:1121–31.PubMed
24.
Wang J, Li Y, Li C, Yu K, Wang Q. Increased expression of matrix metalloproteinase-13 in glioma is associated with poor overall survival of patients. Med Oncol. 2012;29:2432–7.CrossRefPubMed
25.
Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR. MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep. 2009;22:1119–27.PubMed
26.
Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285:19076–84.CrossRefPubMedPubMedCentral
27.
Ma W, Zhang X, Chai J, Chen P, Ren P, Gong M. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol. 2014;35:12467–72.CrossRefPubMed
28.
Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y, et al. MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3. Mol Med Rep. 2015;12:3923–9.PubMed
29.
Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, et al. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through miR-148a. Cell Physiol Biochem. 2015;36:1186–96.CrossRefPubMed
30.
Kim J, Zhang Y, Skalski M, Hayes J, Kefas B, Schiff D, et al. MicroRNA-148a is a prognostic oncomiR that targets Mig6 and Bim to regulate EGFR and apoptosis in glioblastoma. Cancer Res. 2014;74:1541–53.CrossRefPubMedPubMedCentral
31.
Guo SL, Peng Z, Yang X, Fan KJ, Ye H, Li ZH, et al. MiR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci. 2011;7:567–74.CrossRefPubMedPubMedCentral
32.
Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biol. 2014;35:837–44.CrossRefPubMed
33.
Wen Z, Zhao S, Liu S, Liu Y, Li X, Li S. MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. Mol Med Rep. 2015;12:3775–80.PubMed
34.
Wang SH, Li X, Zhou LS, Cao ZW, Shi C, Zhou CZ, et al. MicroRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition. Tumour Biol. 2013;34:3705–12.CrossRefPubMed
35.
Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene. 2014;33:4069–76.CrossRefPubMed
36.
Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog. 2014;53:960–9.PubMed
37.
Li J, Song Y, Wang Y, Luo J, Yu W. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 2013;380:277–82.CrossRefPubMed
38.
Hellman NE, Spector J, Robinson J, Zuo X, Saunier S, Antignac C, et al. Matrix metalloproteinase 13 (MMP13) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1), regulated by the MAPK pathway, are both necessary for Madin-Darby canine kidney tubulogenesis. J Biol Chem. 2008;283:4272–82.CrossRefPubMed
39.
Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, et al. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem. 2012;287:29899–908.CrossRefPubMedPubMedCentral
40.
Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19:1123–30.CrossRefPubMedPubMedCentral
Metadata
Title
MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13
Authors
Jinqi Xue
Zhiguang Chen
Xi Gu
Yang Zhang
Wenhai Zhang
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3926-9

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine

Erratum

Erratum to: Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein

Original Article

MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients

Review

Inhibitory effects of Arhgap6 on cervical carcinoma cells

Original Article

Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma

Original Article

Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits